Cetera Trust Company N.A Sells 2,730 Shares of Evolent Health, Inc. (NYSE:EVH)

Cetera Trust Company N.A reduced its stake in Evolent Health, Inc. (NYSE:EVH) by 29.3% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,600 shares of the technology company’s stock after selling 2,730 shares during the period. Cetera Trust Company N.A’s holdings in Evolent Health were worth $74,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Covestor Ltd grew its holdings in shares of Evolent Health by 138.1% during the third quarter. Covestor Ltd now owns 1,424 shares of the technology company’s stock valued at $40,000 after buying an additional 826 shares during the last quarter. GAMMA Investing LLC grew its holdings in shares of Evolent Health by 5,365.5% during the third quarter. GAMMA Investing LLC now owns 1,585 shares of the technology company’s stock valued at $45,000 after buying an additional 1,556 shares during the last quarter. Quarry LP acquired a new position in shares of Evolent Health during the second quarter valued at about $32,000. Canada Pension Plan Investment Board acquired a new position in shares of Evolent Health during the second quarter valued at about $61,000. Finally, Point72 Asia Singapore Pte. Ltd. grew its holdings in shares of Evolent Health by 2,471.9% during the third quarter. Point72 Asia Singapore Pte. Ltd. now owns 6,507 shares of the technology company’s stock valued at $184,000 after buying an additional 6,254 shares during the last quarter.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on the stock. JMP Securities reduced their price objective on shares of Evolent Health from $27.00 to $18.00 and set a “market outperform” rating for the company in a report on Friday, January 10th. Barclays cut their price target on shares of Evolent Health from $39.00 to $19.00 and set an “overweight” rating on the stock in a report on Monday, November 11th. Citigroup cut their price target on shares of Evolent Health from $21.00 to $18.00 and set a “buy” rating on the stock in a report on Friday, January 10th. Royal Bank of Canada cut their price target on shares of Evolent Health from $20.00 to $17.00 and set an “outperform” rating on the stock in a report on Tuesday, January 14th. Finally, UBS Group cut their price target on shares of Evolent Health from $27.00 to $14.00 and set a “buy” rating on the stock in a report on Thursday, January 16th. One analyst has rated the stock with a hold rating, eleven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Buy” and an average target price of $21.62.

Evolent Health Stock Up 0.3 %

Evolent Health stock opened at $10.03 on Wednesday. Evolent Health, Inc. has a twelve month low of $9.88 and a twelve month high of $35.00. The firm has a 50 day moving average price of $11.60 and a 200-day moving average price of $20.59. The company has a market capitalization of $1.17 billion, a P/E ratio of -11.05 and a beta of 1.45. The company has a quick ratio of 1.04, a current ratio of 1.04 and a debt-to-equity ratio of 0.58.

Evolent Health (NYSE:EVH) last released its earnings results on Thursday, November 7th. The technology company reported ($0.08) earnings per share for the quarter, missing analysts’ consensus estimates of $0.30 by ($0.38). Evolent Health had a negative net margin of 2.93% and a positive return on equity of 6.30%. The company had revenue of $621.40 million for the quarter, compared to the consensus estimate of $625.58 million. During the same period in the prior year, the company earned $0.19 earnings per share. As a group, equities analysts predict that Evolent Health, Inc. will post 0.26 EPS for the current year.

Evolent Health Company Profile

Evolent Health, Inc, through its subsidiary, Evolent Health LLC, offers specialty care management services in oncology, cardiology, and musculoskeletal markets in the United States. The company provides platform for health plan administration and value-based business infrastructure. It offers administrative services, such as health plan services, pharmacy benefits management, risk management, analytics and reporting, and leadership and management; and Identifi, a proprietary technology system that aggregates and analyzes data, manages care workflows, and engages patients.